BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Qilu Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Qilu Pharmaceutical's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07489612-573@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:QLS1410: Phase 2 readout est. (NCT07489612)
DESCRIPTION:QLS1410\, phase 2\, Hypertension.\nStudy: QLS1410 in Participan
 ts With Uncontrolled Hypertension\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/qls1410#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07489612
URL:https://assetmemo.bio/drug/qls1410#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139535-198@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RAY1225: Phase 3 readout est. (NCT07139535)
DESCRIPTION:RAY1225\, phase 3\, Type 2 Diabetes.\nStudy: A Study of RAY1225
  in Participants With Type 2 Diabetes Not Controlled With Diet and Exercis
 e Alone\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ray1225#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07139535
URL:https://assetmemo.bio/drug/ray1225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139548-198@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RAY1225: Phase 3 readout est. (NCT07139548)
DESCRIPTION:RAY1225\, phase 3\, Type 2 Diabetes.\nStudy: A Study of RAY1225
  Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Partic
 ipants With Type 2 Diabetes\nEstimated primary completion: 1 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ray1225#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07139548
URL:https://assetmemo.bio/drug/ray1225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172217-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07172217)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: The Efficacy an
 d Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recu
 rrent CC\nEstimated primary completion: 28 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07172217
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880276-1468@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:QLM3003: Phase 3 readout est. (NCT06880276)
DESCRIPTION:QLM3003\, phase 3\, Atopic Dermatitis.\nStudy: Efficacy and Saf
 ety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic
  Dermatitis\nEstimated primary completion: March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/qlm3003#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06880276
URL:https://assetmemo.bio/drug/qlm3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2\, Non-Small Cell Lung 
 Cancer.\nStudy: QLS5132 Combination Therapy in Advanced Solid Tumors\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07453394
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550465-573@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:QLS1410: Phase 2 readout est. (NCT07550465)
DESCRIPTION:QLS1410\, phase 2.\nStudy: Study of QLS1410 in the Treatment of
  Primary Aldosteronism.\nEstimated primary completion: April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/qls1410#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07550465
URL:https://assetmemo.bio/drug/qls1410#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884891-1467@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:QL2108: Phase 3 readout est. (NCT06884891)
DESCRIPTION:QL2108\, phase 3\, Atopic Dermatitis.\nStudy: A Phase Ⅲ Compa
 rative Study of QL2108 to Dupixent®\nEstimated primary completion: May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ql2108#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06884891
URL:https://assetmemo.bio/drug/ql2108#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07272590-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT07272590)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2.\nStudy: Study of QLC5
 513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patie
 nts With Advanced or Metastatic Malignant Solid Tumors\nEstimated primary 
 completion: June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07272590
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417917-1469@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:QLS12010: Phase 2 readout est. (NCT07417917)
DESCRIPTION:QLS12010\, phase 2.\nStudy: QLS12010 Capsules in Adults With Mo
 derate to Severe Hidradenitis Suppurativa\nEstimated primary completion: 1
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qls12010#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0741
 7917
URL:https://assetmemo.bio/drug/qls12010#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156682-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07156682)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus XEL
 OX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07156682
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05487391-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT05487391)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Study of QL1706 Combined With Platinum-containing Chemothe
 rapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer Aft
 er Complete Surgical Resection.\nEstimated primary completion: 31 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-
 tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05487391
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07344051-1469@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:QLS12010: Phase 2 readout est. (NCT07344051)
DESCRIPTION:QLS12010\, phase 2\, Atopic Dermatitis.\nStudy: A Phase II Stud
 y of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis
 \nEstimated primary completion: September 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/qls12010#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07344051
URL:https://assetmemo.bio/drug/qls12010#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976568-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Iparomlimab and tuvonralimab: Phase 2/3 readout est. (NCT05976568)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2/3.\nStudy: A Study of QL
 1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Tre
 atment in Patients With Advanced Hepatocellular Carcinoma\nEstimated prima
 ry completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05976568
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444086-1055@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:QLC7401: Phase 3 readout est. (NCT07444086)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dys
 lipidemia\nEstimated primary completion: 7 October 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07444086
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3122@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:QLS32015: Phase 2 readout est. (NCT07018050)
DESCRIPTION:QLS32015\, phase 2\, Multiple Myeloma.\nStudy: Phase II Study o
 f QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nEstim
 ated primary completion: November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/qls32015#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/qls32015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927556-573@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLS1410: Phase 2 readout est. (NCT07927556)
DESCRIPTION:QLS1410\, phase 2\, Hypertension.\nStudy: A Phase II Clinical T
 rial to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients Wi
 th Uncontrolled Hypertension Who Are Receiving One or More Background Drug
  Treatments\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/qls1410#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07927556
URL:https://assetmemo.bio/drug/qls1410#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441317-1055@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLC7401: Phase 3 readout est. (NCT07441317)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyp
 erlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07441317
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742138-3369@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QL2109: Phase 3 readout est. (NCT06742138)
DESCRIPTION:QL2109\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate the Ef
 ficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ql2109#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06742138
URL:https://assetmemo.bio/drug/ql2109#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138209-3122@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLS32015: Phase 3 readout est. (NCT07138209)
DESCRIPTION:QLS32015\, phase 3\, Multiple Myeloma.\nStudy: A Study Comparin
 g QLS32015 Monotherapy Versus Pomalidomide\, Dexamethasone (Pd) or Selinex
 or\, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multip
 le Myeloma\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/qls32015#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07138209
URL:https://assetmemo.bio/drug/qls32015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511647-1920@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:QL2106: Phase 3 readout est. (NCT07511647)
DESCRIPTION:QL2106\, phase 3\, Psoriasis.\nStudy: A Phase 3 Clinical Study 
 of QL2106 Injection\nEstimated primary completion: 30 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ql2106#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07511647
URL:https://assetmemo.bio/drug/ql2106#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789796-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT06789796)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: a Study of QL17
 06 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After C
 hemoradiotherapy.\nEstimated primary completion: March 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06789796
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377773-1469@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20280305
DTEND;VALUE=DATE:20280306
SUMMARY:QLS12010: Phase 2 readout est. (NCT07377773)
DESCRIPTION:QLS12010\, phase 2.\nStudy: QLS12010 in Participants With Moder
 ate-to-severe Rheumatoid Arthritis\nEstimated primary completion: 5 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/qls12010#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07377773
URL:https://assetmemo.bio/drug/qls12010#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450378-1055@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:QLC7401: Phase 3 readout est. (NCT07450378)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 in Participants With Heterozygous Familial Hypercholesterolem
 ia (HeFH)\nEstimated primary completion: April 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07450378
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560449-3368@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:QLS4131: Phase 2 readout est. (NCT07560449)
DESCRIPTION:QLS4131\, phase 2.\nStudy: QLS4131 Combination Therapy in Malig
 nant Plasma Cell Neoplasms\nEstimated primary completion: June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/qls4131#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07560449
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025239-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT07025239)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Metastatic Colorectal 
 Cancer.\nStudy: QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plu
 s Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic
  Colorectal Cancer\nEstimated primary completion: July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07025239
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235176-9171@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:QLS1304: Phase 1/2 readout est. (NCT07235176)
DESCRIPTION:QLS1304\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy i
 n the Treatment of ER+/HER2- Breast Cancer Patients\nEstimated primary com
 pletion: 2 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/qls1304#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07235176
URL:https://assetmemo.bio/drug/qls1304#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05690945-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT05690945)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Study of QL1706 in Combination With Chemotherapy in PD-L1-
 Negative Non-small Cell Lung Cancer\nEstimated primary completion: June 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-t
 uvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05690945
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926048-7615@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:QLS5132: Phase 3 readout est. (NCT07926048)
DESCRIPTION:QLS5132\, phase 3.\nStudy: A Study of QLS5132 in Platinum-Resis
 tant Recurrent Ovarian\, Fallopian Tube\, or Primary Peritoneal Cancer\nEs
 timated primary completion: December 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/qls5132#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07926048
URL:https://assetmemo.bio/drug/qls5132#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933432-3368@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20291214
DTEND;VALUE=DATE:20291215
SUMMARY:QLS4131: Phase 3 readout est. (NCT07933432)
DESCRIPTION:QLS4131\, phase 3\, Multiple Myeloma.\nStudy: A Study in Partic
 ipants With Relapsed or Refractory Multiple Myeloma for QLS4131\nEstimated
  primary completion: 14 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/qls4131#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07933432
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06852456-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06852456)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 in Combi
 nation With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for L
 ocally Advanced\, Resectable Esophageal Squamous Cell Carcinoma\nEstimated
  primary completion: December 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06852456
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686576-2261@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT06686576)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: A Study of Neoa
 djuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon 
 Cancer\nEstimated primary completion: December 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06686576
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
